TickerGuard
Buy Day today: Neutral (60) Mixed market breadth · no major macro event
ARVN

Arvinas Inc

Healthcare · Biotechnology

7.40$ -0.3% vs. previous close Closing price · As of: Oct 2, 2026

Statements

Income Statement

Arvinas Inc (ARVN) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Revenue" came in at 250 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Income Statement ARVN
Line item Q4 16 Q1 17 Q2 17 Q3 17 Q4 17 Q1 18 Q2 18 Q3 18 Q4 18 Q1 19 Q2 19 Q3 19 Q4 19 Q1 20 Q2 20 Q3 20 Q4 20 Q1 21 Q2 21 Q3 21 Q4 21 Q1 22 Q2 22 Q3 22 Q4 22 Q1 23 Q2 23 Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 LTM
6.7 1.7 1.7 1.7 2.6 4.1 3.4 3.4 3.4 4.0 4.0 30 4.9 6.2 5.7 7.6 2.2 5.5 5.5 9.3 26 27 34 33 38 33 55 35 -43 25 77 102 59 189 22 42 9.5 16 250 317
23 0.0 16 8.0 7.8 0.0 20 17 0.0 – – – – – – – – – – – 1.6 2.1 1.9 2.1 2.1 1.7 1.6 1.7 1.7 1.7 1.7 – 1.6 – – – 1.2 1.1 9.0 –
6.7 1.7 1.7 1.7 2.6 4.1 3.4 3.4 3.4 4.0 4.0 30 4.9 6.2 5.7 7.6 2.2 5.5 5.5 9.3 25 24 32 31 36 31 53 33 -45 24 75 102 59 189 22 42 8.3 15 241 305
20 7.1 7.8 7.2 6.7 7.1 10 13 15 14 16 17 20 22 23 30 33 35 43 41 62 64 75 78 98 95 103 86 95 84 94 87 83 91 69 65 61 60 53 238
3.2 0.9 0.6 0.9 1.2 1.2 1.6 4.3 5.8 5.6 6.4 8.0 7.3 7.9 8.8 9.3 12 12 14 16 19 20 24 20 15 25 26 23 27 24 31 76 34 27 25 22 22 19 24 87
23 8.0 8.4 8.1 7.9 8.4 12 17 20 20 22 25 28 30 32 39 45 47 57 57 79 82 98 95 111 119 128 107 121 107 123 163 117 117 94 86 80 77 77 320
-16 -6.3 -6.7 -6.4 -5.3 -4.3 -8.5 -14 -17 -16 -18 5.5 -23 -23 -26 -32 -43 -42 -52 -47 -54 -58 -66 -64 -75 -88 -75 -74 -165 -83 -49 -60 -58 71 -72 -44 -72 -63 164 -14
0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 1.2 1.8 3.4 5.7 7.1 – – 7.1 – – – – – – – – – – –
-14 -6.2 -6.7 -6.4 -4.7 -4.2 -7.9 -13 -16 -14 -17 -18 -21 -22 -25 -31 -42 -41 -50 -47 -53 -59 -67 -64 -72 -82 -67 -64 -153 -69 -35 -49 -46 83 -62 -35 -67 -58 170 10
-0.1 0.0 0.0 0.0 0.6 0.1 0.1 0.2 -1.4 -1.6 0.2 -24 -1.9 0.4 0.3 0.2 -1.8 0.3 1.2 0.2 0.1 4.5 3.4 2.2 11 -0.4 -0.3 0.1 1.6 0.1 0.2 0.6 -0.4 0.2 -0.3 0.3 0.2 0.1 0.2 0.8
-14 -6.2 -6.7 -6.4 -4.7 -4.2 -7.9 -13 -16 -14 -17 -18 -21 -22 -25 -31 -42 -41 -50 -47 -53 -63 -70 -66 -83 -82 -67 -64 -155 -69 -35 -49 -45 83 -61 -35 -67 -58 169 9.3
– -6.2 -6.6 -6.3 -4.6 -4.0 -7.7 -13 -16 -14 -17 -17 -20 -21 -24 -30 -40 -41 -49 -46 -51 -55 -62 -59 -67 -80 -64 -62 -152 -68 -33 -48 -44 84 -60 -34 -66 -56 159 2.9

LTM = last twelve months (sum of the four most recent quarters).

Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?